Nordion's (NYSE:NDZ) Medical Isotope Business Disappoints Some

Although Canaccord Genuity considers the pace of the growth of Nordion Inc (NYSE:NDZ) better than expected, others had hopes of a faster trajectory, which seems to be weighing on the stock.

Canaccord says, "Nordion will report Q4 financial results after the market close on Thursday, January 20, and will hold a conference call to discuss these results at 9:30 am EST the next day. Our focus will be less on the operating performance and more on the overall level of financial disclosure provided by the company. We believe that recent share price weakness is related to last week’s operational update, which showed the Medical Isotopes business was performing better than our conservative estimates but was likely a disappointment to others that assumed much more rapid uptake of moly-99 following the restart of the NRU."

Canaccord Genuity reiterates a "Buy" rating on Nordion Inc (NDZ), which closed Tuesday at $10.24, up $0.03, or 0.29 percent. Canaccord has a price target of $14 on Nordion.